BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

858 related articles for article (PubMed ID: 9741222)

  • 21. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
    Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAV chemotherapy (CCNU, melphalan, etoposide) as salvage treatment for relapsing or resistant Hodgkin's disease.
    Brusamolino E; Castelli G; Pagnucco G; Orlandi E; Malagó D; Lazzarino M; Bernasconi C
    Haematologica; 1990; 75(4):340-5. PubMed ID: 1703510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
    Mjaaland I; Ganser D; Freitag EM; Bohndorf W
    Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involved-field radiotherapy for advanced Hodgkin's lymphoma.
    Aleman BM; Raemaekers JM; Tirelli U; Bortolus R; van 't Veer MB; Lybeert ML; Keuning JJ; Carde P; Girinsky T; van der Maazen RW; Tomsic R; Vovk M; van Hoof A; Demeestere G; Lugtenburg PJ; Thomas J; Schroyens W; De Boeck K; Baars JW; Kluin-Nelemans JC; Carrie C; Aoudjhane M; Bron D; Eghbali H; Smit WG; Meerwaldt JH; Hagenbeek A; Pinna A; Henry-Amar M;
    N Engl J Med; 2003 Jun; 348(24):2396-406. PubMed ID: 12802025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
    Petera J; Macharová H; Pohanková R; Malír A; Coupek P; Konecný M; Patera J; Pecina J; Drbal J; Koukalová H; Vásová I
    Neoplasma; 2000; 47(2):129-32. PubMed ID: 10985481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
    Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
    Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease.
    Salvagno L; Sorarù M; Sotti G; Aversa S; Chiarion Sileni V; Mazzarotto R; Scarzello G; Bianco A; Pappagallo GL; Fiorentino MV
    Ann Oncol; 1995 Feb; 6(2):173-9. PubMed ID: 7540419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
    Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S
    Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.
    Bonadonna G; Santoro A; Bonfante V; Valagussa P
    Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cured from Hodgkin's disease].
    Brice P
    Bull Cancer; 2002; 89(7-8):666-70. PubMed ID: 12206979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hodgkin's disease: controversies and challenges for the future.
    Tura S; Canellos G; Goldstone A; Longo D; McMillan A; Urba W; Zinzani PL
    Haematologica; 1991; 76(4):263-79. PubMed ID: 1724436
    [No Abstract]   [Full Text] [Related]  

  • 36. [Recurrence of Hodgkin's disease after advanced primary stages. German Hodgkin's Study Group].
    Fuchs R; Löffler M; Pfreundschuh M; Dölken G; Gerhartz H; Hagen-Aukamp U; Hiller E; Petsch S; Pflüger KH; Rühl U
    Med Klin (Munich); 1992 Nov; 87(11):555-62. PubMed ID: 1281905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
    Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
    J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
    Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G
    Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
    J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.